سلامة دواء أداليموماب: تحليل قاعدة بيانات نظام الإبلاغ عن الآثار الجانبية
DOI:
https://doi.org/10.35516/jjps.v16i3.629الكلمات المفتاحية:
أداليموماب، الآثار الجانبية شديدة الخطورة، قاعدة ببانات، أمراض الروماتيزم، هوميراالملخص
Not Applicable
الهدف: تحديد مدى سلامة دواء أداليموماب و بدائله الحيوية لكل إستخدام معتمد من خلال تحليل الأثار الجانبية التي تم الإبلاغ عنها إلى قاعدة بيانات نظام الإبلاغ عن الآثار الجانبية التابعة لإدارة الغذاء و الدواء الأمريكية
الطريقة: قمنا بإجراء تحليل إحصائي رجعي لتقارير الآثار الجانبية الموثقة من عام 2002 الى عام 2022. كما قمنا بمقارنة تقارير الآثار الجانبية لدواء الأدابيموماب و بدائله الحيوية مع البدائل الأخرى المتاحة حاليا لكل إستخدام.
النتائج: بالمجمل، تم الإبلاغ عن 543.873 تقرير لدواء الأداليموماب. من بين هؤلاء كان هناك 49.8٪ من الحالات شديدة الخطورة. الحاجة للذهاب إلى المستشفى كان أكثر الأثار الجانبية شيوعا. الذكور، وكبار السن (<60)، وإستخدام أكثر من دواء في نفس الوقت كانوا أكثر العوامل إرتباطا بالآثار الجانبية شديدة الخطورة.
الخلاصة: تشير نتائج هذه الدراسة إلى أن دواء أداليموماب يعتبر أكثر أمانا مقارنة بالبدائل البيولوجية المتاحة حاليا.
المراجع
Bain B, Brazil M. Adalimumab. Nat Rev Drug Discov. 2003;2(9):693-694. doi:10.1038/nrd1182 DOI: https://doi.org/10.1038/nrd1182
Zhao S, Chadwick L, Mysler E, Moots RJ. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis. Curr Rheumatol Rep. 2018;20(10):57. Published 2018 Aug 9. doi:10.1007/s11926-018-0769-6 DOI: https://doi.org/10.1007/s11926-018-0769-6
Barut K, Adrovic A, Şahin S, Kasapçopur Ö. Juvenile Idiopathic Arthritis. Balkan Med J. 2017;34(2):90-101. doi:10.4274/balkanmedj.2017.0111 DOI: https://doi.org/10.4274/balkanmedj.2017.0111
Salvarani C, Pipitone N, Catanoso M, et al. Adalimumab in psoriatic arthritis. J Rheumatol Suppl. 2012;89:77-81. doi:10.3899/jrheum.120251 DOI: https://doi.org/10.3899/jrheum.120251
van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136-2146. doi:10.1002/art.21913 DOI: https://doi.org/10.1002/art.21913
Serghini M, Haddad W, Jeddi H, et al. Indications et résultats de l'adalimumab au cours de la maladie de Crohn [Efficacy and safety of Adalimumab in Crohn's disease]. Tunis Med. 2012;90(2):101-107.
Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257-65.e653. doi:10.1053/j.gastro.2011.10.032 DOI: https://doi.org/10.1053/j.gastro.2011.10.032
Croom KF, McCormack PL. Adalimumab: in plaque psoriasis. Am J Clin Dermatol. 2009;10(1):43-50. doi:10.2165/0128071-200910010-00008 DOI: https://doi.org/10.2165/0128071-200910010-00008
Kim ES, Garnock-Jones KP, Keam SJ. Adalimumab: A Review in Hidradenitis Suppurativa. Am J Clin Dermatol. 2016;17(5):545-552. doi:10.1007/s40257-016-0220-6 DOI: https://doi.org/10.1007/s40257-016-0220-6
LaMattina KC, Goldstein DA. Adalimumab for the treatment of uveitis. Expert Rev Clin Immunol. 2017;13(3):181-188. doi:10.1080/1744666X.2017.1288097 DOI: https://doi.org/10.1080/1744666X.2017.1288097
Lu X, Hu R, Peng L, Liu M, Sun Z. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis. Front Immunol. 2021;12:638444. Published 2021 Apr 6. doi:10.3389/fimmu.2021.638444 DOI: https://doi.org/10.3389/fimmu.2021.638444
Nanau RM, Neuman MG. Safety of anti-tumor necrosis factor therapies in arthritis patients. J Pharm Pharm Sci. 2014;17(3):324-361. doi:10.18433/j3wp4f DOI: https://doi.org/10.18433/J3WP4F
Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013;72(4):517-524. doi:10.1136/annrheumdis-2011-201244 DOI: https://doi.org/10.1136/annrheumdis-2011-201244
Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76(5):840-847. doi:10.1136/annrheumdis-2016-210310 DOI: https://doi.org/10.1136/annrheumdis-2016-210310
Goettel AM, DeClercq J, Choi L, Graham TB, Mitchell AA. Efficacy and Safety of Abatacept, Adalimumab, and Etanercept in Pediatric Patients With Juvenile Idiopathic Arthritis. J Pediatr Pharmacol Ther. 2021;26(2):157-162. doi:10.5863/1551-6776-26.2.157 DOI: https://doi.org/10.5863/1551-6776-26.2.157
Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123-131. doi:10.1136/annrheumdis-2019-215386 DOI: https://doi.org/10.1136/annrheumdis-2019-215386
Plosker GL, Lyseng-Williamson KA. Adalimumab: in Crohn's disease. BioDrugs. 2007;21(2):125-134. doi:10.2165/00063030-200721020-00007 DOI: https://doi.org/10.2165/00063030-200721020-00007
Ogata H, Hagiwara T, Kawaberi T, Kobayashi M, Hibi T. Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study. Intest Res. 2021;19(4):419-429. doi:10.5217/ir.2020.00033 DOI: https://doi.org/10.5217/ir.2020.00033
Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus Adalimumab in Plaque Psoriasis. N Engl J Med. 2021;385(2):130-141. doi:10.1056/NEJMoa2102388 DOI: https://doi.org/10.1056/NEJMoa2102388
Lu JW, Huang YW, Chen TL. Efficacy and safety of adalimumab in hidradenitis suppurativa: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2021;100(22):e26190. doi:10.1097/MD.0000000000026190 DOI: https://doi.org/10.1097/MD.0000000000026190
Suhler EB, Jaffe GJ, Fortin E, et al. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Ophthalmology. 2021;128(6):899-909. doi:10.1016/j.ophtha.2020.10.036 DOI: https://doi.org/10.1016/j.ophtha.2020.10.036
FDA Adverse Event Reporting System (FAERS) Public Dashboard. Available at
https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard. Accessed June 15, 2022.
Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations. Available at: https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/purple-book-lists-licensed-biological-products-reference-product-exclusivity-and-biosimilarity-or. Accessed June 15, 2022.
Gerriets V, Goyal A, Khaddour K. Tumor Necrosis Factor Inhibitors. In: StatPearls. Treasure Island (FL): StatPearls Publishing; April 30, 2022.
Leonardi C, Papp K, Strober B, et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol. 2011;12(5):321-337. doi:10.2165/11587890-000000000-00000 DOI: https://doi.org/10.2165/11587890-000000000-00000
van Vollenhoven RF. Sex differences in rheumatoid arthritis: more than meets the eye... BMC Med. 2009;7:12. Published 2009 Mar 30. doi:10.1186/1741-7015-7-12 DOI: https://doi.org/10.1186/1741-7015-7-12
Cross RK, Chiorean M, Vekeman F, Xiao Y, Wu E, Chao J, et al. (2019) Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system. PLoS ONE 14(12): e0225572.
https://doi.org/10.1371/journal.pone.0225572 DOI: https://doi.org/10.1371/journal.pone.0225572
Araujo AGS, Borba HHL, Tonin FS, et al. Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS). BioDrugs. 2018;32(4):377-390. doi:10.1007/s40259-018-0285-2 DOI: https://doi.org/10.1007/s40259-018-0285-2
Nurminen M. To use or not to use the odds ratio in epidemiologic analyses?. Eur J Epidemiol. 1995;11(4):365-371. doi:10.1007/BF01721219 DOI: https://doi.org/10.1007/BF01721219
Tanni, K.A., Truong, C.B., Almahasis, S. et al. Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. BioDrugs 35, 239–254 (2021). https://doi.org/10.1007/s40259-020-00466-3 DOI: https://doi.org/10.1007/s40259-020-00466-3
Hakooz, N. (2023). Pharmacogenetics and Personalized Medicines . Jordan Journal of Pharmaceutical Sciences, 16(2), 444.
https://doi.org/10.35516/jjps.v16i2.1483 DOI: https://doi.org/10.35516/jjps.v16i2.1483
Hjazeen, R. (2023). Community Pharmacists’ Perspectives toward Continuing Professional Development: A Qualitative Study. Jordan Journal of Pharmaceutical Sciences, 16(2), 449. https://doi.org/10.35516/jjps.v16i2.1488 DOI: https://doi.org/10.35516/jjps.v16i2.1488
Alabbadi, I., Al-Oweidi, A. K. ., Daher, A., BaniHani, A., & Awidi, A. (2023). Hemophilia in Jordan: An Economic Burden Dilemma of Rare Disease. Jordan Journal of Pharmaceutical Sciences, 16(2), 356–367. https://doi.org/10.35516/jjps.v16i2.1462 DOI: https://doi.org/10.35516/jjps.v16i2.1462
